These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 19664754

  • 21. Foveal Serous Retinal Detachment in Juvenile Idiopathic Arthritis-associated Uveitis.
    Liang F, Terrada C, Ducos de Lahitte G, Quartier P, Lehoang P, Thorne JE, Bodaghi B.
    Ocul Immunol Inflamm; 2016 Aug; 24(4):386-91. PubMed ID: 26171661
    [Abstract] [Full Text] [Related]

  • 22. Risk of Hypotony in Juvenile Idiopathic Arthritis-Associated Uveitis.
    Moradi A, Stroh IG, Reddy AK, Hornbeak DM, Leung TG, Burkholder BM, Thorne JE.
    Am J Ophthalmol; 2016 Sep; 169():113-124. PubMed ID: 27345732
    [Abstract] [Full Text] [Related]

  • 23. Chronic Non-infectious Uveitis in Patients with Juvenile Idiopathic Arthritis.
    Kolomeyer AM, Tu Y, Miserocchi E, Ranjan M, Davidow A, Chu DS.
    Ocul Immunol Inflamm; 2016 Aug; 24(4):377-85. PubMed ID: 26902465
    [Abstract] [Full Text] [Related]

  • 24. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR, Moudgil A, Vo A, Jordan SC.
    Am J Health Syst Pharm; 2005 Feb 15; 62(4):391-6. PubMed ID: 15745891
    [Abstract] [Full Text] [Related]

  • 25. Treatment Options for Juvenile Idiopathic Arthritis (JIA) Associated Uveitis.
    Amin RM, Miserocchi E, Thorne JE, Hornbeak D, Jabs DA, Zierhut M.
    Ocul Immunol Inflamm; 2016 Feb 15; 24(1):81-90. PubMed ID: 26652068
    [Abstract] [Full Text] [Related]

  • 26. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.
    García-De-Vicuña C, Díaz-Llopis M, Salom D, Bou R, Díaz-Cascajosa J, Cordero-Coma M, Ortega G, Ortego-Centeno N, Suarez-De-Figueroa M, Cruz-Martínez J, Fonollosa A, Blanco R, García-Aparicio ÁM, Benítez-Del-Castillo JM, Antón J.
    Mediators Inflamm; 2013 Feb 15; 2013():560632. PubMed ID: 24489444
    [Abstract] [Full Text] [Related]

  • 27. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
    Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF.
    Ophthalmology; 2012 Aug 15; 119(8):1575-81. PubMed ID: 22525047
    [Abstract] [Full Text] [Related]

  • 28. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Clin Transplant; 2002 Feb 15; 16(1):60-8. PubMed ID: 11982617
    [Abstract] [Full Text] [Related]

  • 29. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.
    Arch Neurol; 2009 Apr 15; 66(4):483-9. PubMed ID: 19364933
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, AIN457A2208 Study Group.
    Ophthalmology; 2015 May 15; 122(5):939-48. PubMed ID: 25638011
    [Abstract] [Full Text] [Related]

  • 31. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis.
    Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP.
    Am J Ophthalmol; 2007 Apr 15; 143(4):647-55. PubMed ID: 17224116
    [Abstract] [Full Text] [Related]

  • 32. Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis.
    Tappeiner C, Heinz C, Roesel M, Heiligenhaus A.
    Acta Ophthalmol; 2011 Sep 15; 89(6):e521-7. PubMed ID: 21586097
    [Abstract] [Full Text] [Related]

  • 33. Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study.
    Rypdal V, Glerup M, Songstad NT, Bertelsen G, Christoffersen T, Arnstad ED, Aalto K, Berntson L, Fasth A, Herlin T, Ekelund M, Peltoniemi S, Toftedal P, Nielsen S, Leinonen S, Bangsgaard R, Nielsen R, Rygg M, Nordal E, Nordic Study Group of Pediatric Rheumatology.
    Ophthalmology; 2021 Apr 15; 128(4):598-608. PubMed ID: 32866542
    [Abstract] [Full Text] [Related]

  • 34. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS.
    Ophthalmology; 2006 Feb 15; 113(2):308-14. PubMed ID: 16406545
    [Abstract] [Full Text] [Related]

  • 35. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R.
    Clin Rheumatol; 2020 Mar 15; 39(3):847-851. PubMed ID: 31897953
    [Abstract] [Full Text] [Related]

  • 36. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis.
    Mangge H, Heinzl B, Grubbauer HM, El-Shabrawi Y, Schauenstein K.
    Rheumatol Int; 2003 Sep 15; 23(5):258-61. PubMed ID: 12687288
    [Abstract] [Full Text] [Related]

  • 37. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis.
    El-Shabrawi Y, Hermann J.
    Ophthalmology; 2002 Dec 15; 109(12):2342-6. PubMed ID: 12466181
    [Abstract] [Full Text] [Related]

  • 38. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 39. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab).
    Sloand EM, Scheinberg P, Maciejewski J, Young NS.
    Ann Intern Med; 2006 Feb 07; 144(3):181-5. PubMed ID: 16461962
    [Abstract] [Full Text] [Related]

  • 40. [Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].
    Hernández Garfella ML, Díaz Llopis M, Salom Alonso D, Cervera Taulet E.
    Arch Soc Esp Oftalmol; 2004 Dec 07; 79(12):593-8. PubMed ID: 15627927
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.